Zimmer Biomet (NYSE:ZBH) strengthened liquidity with new revolvers while acquiring Pacira’s iovera pain‑relief business for up to $140M and announcing a Bengaluru tech center that will hire 500 staff over three years, aligning funding, M&A and talent for growth.
Previous Week Recap
- Zimmer Biomet Refis Unsecured Revolvers: Zimmer Biomet (ZBH) refinanced liquidity June 26, 2026: new unsecured $1.5B five‑year revolver (matures 2031, two one‑year extensions) and $1.25B 364‑day revolver (matures 2027).
- Zimmer To Buy Pacira iovera for Up To $140M: Zimmer Biomet will buy Pacira’s iovera pain‑relief business for up to $140M: $70M upfront plus $70M in revenue‑based milestones through 2031. Zimmer gains full rights; deal closes Q3 2026.
- Zimmer Biomet To Hire 500 Bengaluru Tech: Zimmer Biomet plans to hire 500 staff over three years for a new Bengaluru tech center: ~2/3 in tech roles (software, product, R&D) and the rest in quality, regulatory and finance.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.